These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22378156)

  • 1. Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.
    Liu Y; Jeong H; Takahashi H; Drozda K; Patel SR; Shapiro NL; Nutescu EA; Cavallari LH
    Clin Pharmacol Ther; 2012 Apr; 91(4):660-5. PubMed ID: 22378156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.
    Cavallari LH; Vaynshteyn D; Freeman KM; Wang D; Perera MA; Takahashi H; Drozda K; Patel SR; Jeong H
    Pharmacogenet Genomics; 2013 Apr; 23(4):228-31. PubMed ID: 23376925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
    Takahashi H; Wilkinson GR; Caraco Y; Muszkat M; Kim RB; Kashima T; Kimura S; Echizen H
    Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing warfarin dose requirements in African-Americans.
    Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
    Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
    Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
    Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
    Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
    Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.
    Linder MW; Looney S; Adams JE; Johnson N; Antonino-Green D; Lacefield N; Bukaveckas BL; Valdes R
    J Thromb Thrombolysis; 2002 Dec; 14(3):227-32. PubMed ID: 12913403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C9 genetic polymorphisms and warfarin.
    Redman AR; Dickmann LJ; Kidd RS; Goldstein JA; Ritchie DM; Hon YY
    Clin Appl Thromb Hemost; 2004 Apr; 10(2):149-54. PubMed ID: 15094935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and clinical predictors of warfarin dose requirements in African Americans.
    Cavallari LH; Langaee TY; Momary KM; Shapiro NL; Nutescu EA; Coty WA; Viana MA; Patel SR; Johnson JA
    Clin Pharmacol Ther; 2010 Apr; 87(4):459-64. PubMed ID: 20072124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.
    Kealey C; Chen Z; Christie J; Thorn CF; Whitehead AS; Price M; Samaha FF; Kimmel SE
    Pharmacogenomics; 2007 Mar; 8(3):217-25. PubMed ID: 17324110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
    Lu Y; Yang J; Zhang H; Yang J
    Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
    Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
    Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.
    Tai G; Farin F; Rieder MJ; Dreisbach AW; Veenstra DL; Verlinde CL; Rettie AE
    Pharmacogenet Genomics; 2005 Jul; 15(7):475-81. PubMed ID: 15970795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.